Abstract
Breast cancer is a concerning worldwide disease that is fatal. Although treatments had been developed over the past, prevention was still on the road of discovery. There are still no vaccines that have been approved for treatment or prevention by the year 2023. In this review, the feasibility of two types of vaccines and potential targets was assessed, with links to future paths of breast cancer vaccine investigations. Messenger RNA (mRNA) vaccine and a tissue-specific self-protein -Lactalbumin vaccination are two types of potential vaccines facing towards breast cancer with different pathogenesis of overexpression in HER2 or the -Lactalbumin. Sufficient research had been done on the mRNA vaccines showing HER2 as a potential target that shows the most positive result in vaccine clinical trials. Research on -Lactalbumin were less compared to mRNA vaccines, but the results showed that -Lactalbumin was immunogenic enough to induce effective tumor immunity in healthy adult women.
Published Version (
Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call